Inovio Pharmaceuticals Inc. released its financial results for the first quarter of 2025, highlighting a decrease in total operating expenses to $25.1 million, down from $31.5 million during the same period in 2024. The company reported a net loss of $19.7 million for the quarter, a reduction from the $30.5 million net loss in the first quarter of 2024. Research and development expenses decreased to $16.1 million from $20.9 million, largely due to reduced drug manufacturing and immunology expenses related to INO-3107, along with lower contract labor expenses and expensed inventory. General and administrative expenses also saw a decline, reducing to $9.0 million from $10.6 million, primarily due to decreased legal expenses and reduced stock-based compensation for employees and consultants. As of March 31, 2025, Inovio reported cash, cash equivalents, and short-term investments of $68.4 million, compared to $94.1 million at the end of 2024. The company projects its current cash resources to support operations into the first quarter of 2026, with an estimated net cash burn of approximately $22 million for the second quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.